Shuyan Wan

Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study

David Roth, David R. Nelson, Annette Bruchfeld et al. · The Lancet · 2015 · 663 citations · Full text

Hepatic Disorders, Hepatitis C, Viral Hepatitis +10

Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection

Stefan Zeuzem, Reem Ghalib, K. Rajender Reddy et al. · Annals of Internal Medicine · 2015 · 514 citations

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.

Brian I. Rini, Elizabeth R. Plimack, V.P. Stus et al. · Journal of Clinical Oncology · 2019 · 118 citations

Immunology, Imdc Intermediate/poor Risk, Pharmacotherapy +17

Activation tagging, an efficient tool for functional analysis of the rice genome

Shuyan Wan, Jinxia Wu, Zhiguo Zhang et al. · Plant Molecular Biology · 2008 · 92 citations

Biology, Functional Genomics, Engineering +14

Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials

Edward Gane, Stephen Pianko, Stuart K. Roberts et al. · ˜The œLancet. Gastroenterology & hepatology · 2017 · 27 citations

Hepatic Disorders, Hepatology, Hepatitis C +13